NCT00273013View on ClinicalTrials.gov

Study With GW274150 In Patients With Mild Asthma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 15, 2004

Primary Completion Date

October 28, 2005

Study Completion Date

October 28, 2005

Conditions
Asthma
Interventions
DRUG

GW274150

GW274150 will be available as 30 mg white oval tablets.

DRUG

Singulair

Singulair will be available as over encapsulated 10 mg orange tablets.

DRUG

Placebo

Matching placebo for Singulair and GW274150 will be available.

Trial Locations (2)

M23 9LT

GSK Investigational Site, Manchester

SE1 9RT

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00273013 - Study With GW274150 In Patients With Mild Asthma | Biotech Hunter | Biotech Hunter